Phase 1 N=42 Malaria: Relative Bioavailability and Food Effect of DSM265
Healthy Volunteers
Primary: Cmax — 15300; 14200; 11200 NG/ML — p=0.4847
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=12 Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
Influenza A Subtype H5N1 Infection
Primary: Number of Participants With a Four-fold Increase in Stem-specific Antibody Titers (H5, Hemagglutinin Antibody) Against H5N1 at Day 29 After Vaccination With the Seasonal…
N/A N=116 Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Other Acute Illnesses Presenting to the Hospital · Heart Failure · Pneumonia
Primary: Change in Frequency of Point-of-care Ultrasound Use for Diagnostic and Procedural Applications at Baseline and 6-9 Months — 12.9; 4.0 Number of POCUS Exams/week
Phase 4 N=50 Post-Op Lidocaine Patch
Pain, Postoperative
Primary: 12-hour Postoperative Pain Scores — 33.5; 28.8 score on a scale
N/A N=44 NATO Litter: Fluid Immersion System (FIS) Versus Traditional Mattress for Pressure Dispersion
Pressure Distribution · Military Litters · Peak Pressure Index
Primary: Pressure Redistribution: Peak Pressure Index — 320.63; 264.8107; 328.5933; 267.1014 mm Hg — p=0.0001
N/A N=20 Single Stage Root Coverage for Gingival Recession With or Without Free Gingival Graft
Gingival Recession
Primary: Recession Height — 1.0; 0.9 mm
Phase 2 N=3 Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)
Aortic Valve Stenosis
Primary: Total Work Performed During a Maximal-effort Exercise Test
Phase 3 N=299 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Cytomegalovirus Infections
Primary: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months — 14.1; 42.6 percentage of participants
Phase 3 N=30 Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
Opioid Dependence
Primary: Successful Induction Onto XR-NTX — 8 Participants
Phase 2 N=16 Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
Melanoma
Primary: Relapse-Free Survival — 12 Participants
Phase 1 N=79 Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Advanced Solid Tumors · Gastric Cancer · Transitional Cell Carcinoma of the Bladder
Primary: Number of Participants With Protocol Specified Dose-limiting Toxicities (Part 1 Only). — 0; 0; 0; 0 Participants
Phase 2 N=9 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Cushing's Syndrome · Ectopic Corticotropin Syndrome · Adrenal Adenoma
Primary: Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12 — -99.0; -97.8; -94.5; -91.5 percentage change
Phase 3 N=25 Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases
Primary Immune Deficiency Disorder
Primary: Number of Serious Bacterial Infections Per Person-Year on Treatment — 0 SBI per patient year
Phase 2 N=305 Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16 — -7.2; -17.1; -49.9; -55.9 Percent change
Phase 2 N=258 A Multi-center 12-week Study of HMS5552 in T2DM
Diabetes Mellitus, Type 2
Primary: After 12-week Treatment, the Change From Baseline in HbA1c — -0.39; -0.65; -0.79; -1.12 Percentage of glycated hemoglobin